THE ONCOLOGY RESEARCH INFORMATION EXCHANGE NETWORK (ORIEN) and HudsonAlpha Institute of Biotechnology announced a new collaboration to advance cancer research and care called The ORIEN Avatar Research Program. Under the agreement, HudsonAlpha will provide DNA sequences for 20,000 patient samples, tumor and non-tumor, by 2019 to identify the genetic disturbances and mutations of each patient’s... […]
ST. JUDE CHILDREN’S RESEARCH HOSPITAL and The Wellcome Trust Sanger Institute, UK, agreed to a full exchange of cancer mutation data to support the discovery and understanding of genetic mutations causing cancers. The agreement will provide regular updates and exchanges of data between both institutions to ensure the best support for research in all areas... […]
GOLDEN MEDITECH HOLDINGS LTD., a Hong Kong-based healthcare enterprise, and MD Anderson Cancer Center announced the creation of Cellenkos Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of $10 million with warrants to purchase an additional $10 million... […]
ELI LILLY & CO. said that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union with advanced soft tissue sarcoma not amenable to curative treatment with... […]
FDA has recommended against the use of ovarian cancer screening tests, regardless of risk level.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies for August. For further information, contact the principal investigator listed.
FDA granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.
Celsion Corp. said NIH has conducted an independent retrospective analysis of data from the intent-to-treat population of the Company's HEAT Study, a 701-patient study investigating ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation in primary hepatocellular carcinoma.
Combining two immunotherapy drugs upfront for advanced melanoma appears to increase the two-year survival rate over that achieved with a single agent, according to an analysis of results from a multi-center phase II clinical trial, scientists report.
